Clinical trial

A Retrospective Clinical Study on the Impact of Nutritional Status on the Analgesic Effect of Fentanyl Transdermal Patches in Cancer Pain Patients

Name
TDFCANCERPAIN20230101
Description
The goal of this observational study is to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status.
Trial arms
Trial start
2023-03-01
Estimated PCD
2023-07-31
Trial end
2023-12-31
Status
Completed
Treatment
transdermal fentanyl
Adult cancer pain patients switched from oral opioid to TDF
Arms:
Group A
Size
151
Primary endpoint
11-point numeric rating scale (NRS) after TDF treatment
in 1 week
the occasions that breakthrough pain attacks per day after TDF treatment
in 1 week
The dose adjustment of TDF
in 1 week
The kinds of other analgesics combined with TDF
in 1 week
Eligibility criteria
Inclusion Criteria: * Cancer pain patients admitted to our hospital; * Cancer pain patients switched from oral sustained-release strong opioid analgesics to fentanyl transdermal patches during the hospital stay. Exclusion Criteria: * Patients who have been switched to fentanyl transdermal patches after titration with an analgesic pump; * Patients using fentanyl transdermal patches in combination with other oral sustained-release strong opioid analgesics; * Patients using fentanyl transdermal patches in combination with an analgesic pump; * Patients who have used fentanyl transdermal patches for less than 3 days; * Patients with postoperative pain; * Patients with allergies; * Patients who are pregnant women; * Patients with missing data.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 151, 'type': 'ACTUAL'}}
Updated at
2024-04-17

1 organization

1 product

2 indications

Product
Fentanyl
Indication
Cancer Pain